The Latest Developments Of Specific-Spectrum, Anti-Staphyloccal Agents Using In-vitro, In-vivo And Human Clinical Data, 5-6 March 2012, London

Main Category: Conferences
Article Date: 08 Feb 2012 - 0:00 PST


Now in its 14th year, Superbugs & Superdrugs is a well established antibacterial event that promises to be the perfect forum for networking and problem solving with senior industry executives from the pharmaceutical sector.

The event will be held on the 5&6 of March at the Copthorne Tara Hotel, London and will be made up of case-study focused presentations, highlighting success stories and lessons to be learnt. With multidrug resistance ever-increasing on a worldwide scale, advances in antibacterial development have never been more important and this event will be the perfect opportunity to be kept updated with advances in the antibacterial sector.

Key Benefits of Attending:

• Developments of specific-spectrum, anti-staphyloccal agents using in-vitro, in-vivo and human clinical data
  
  
• Evaluating methods to identify beta-lactam synergists and modification to counter bacterial resistance
  
  
• Discussing anti(myco) bacterial drug discovery and development in TB research
  
  
• Exploring new perspectives on the treatment of CDI
  
  
• Updates in anti-fungal and vaccine therapies
  
  
• Assess monoclonal antibody prophylaxis as an alternative approach
  
  
• Combating antibacterial resistance in developing markets

Key Presentations Include:

Development of vaccines for the prevention of antibiotic-resistant bacterial infections

• Identification of vaccine targets for bacterial pathogens
• Preclinical evaluation of candidate vaccines
• Focus on staphylococcus aurues and Clostridum difficle

Jon Heinrichs, Director, Microbial Vaccines, Merck

Novel LpxC inhibitors for treatment of gram-negative infections

• The SAR of a new series of LpxC inhibitors
• PK and strategies to lower human dose projections
• X-ray crystallographic analysis of bound inhibitors
• MIC90s for multiple gram-negatives

Justin Montgomery, Senior Principal Scientist, Pfizer


For further details and the full programme visit http://www.smi-online.co.uk/2012superbugs23.asp 



• Additional
• References
• Citations